NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2025. All Rights Reserved.
Date: Wednesday, April 30, 2025 9:25

Release 2.158
Noroseal 2.6g Intramammary Suspension for Cattle
 
Species: Cattle
Therapeutic indication: Pharmaceuticals: Antimicrobials: Intramammaries: Dry cow (non antibacterial)
Active ingredient: Bismuth Subnitrate
Product:Noroseal 2.6g Intramammary Suspension for Cattle
Product index: NoroSeal
Cattle - milk: Zero hours
Cattle - meat: Zero days
Incorporating:
Qualitative and quantitative composition
Each 4g Intramammary syringe contains:
Active substance(s):
Bismuth subnitrate, heavy
2.6g
Excipients:
For a full list of excipients, see section Pharmaceutical Particulars
Pharmaceutical form
Intramammary suspension.
Light brown suspension.
Clinical particulars
Target species
Cattle (dairy cows)
Indications for use, specifying the target species
Prevention of new intramammary infections throughout the dry period.
In cows considered likely to be free of sub-clinical mastitis, the product may be suitable for use on its own in dry cow management for mastitis control.
Selection of cows for treatment with the product should be based on veterinary clinical judgement. Selection criteria may be based on the mastitis and cell count history of individual cows, or recognised tests for the detection of sub-clinical mastitis such as bacteriological sampling.
Contraindications
See section, "Use during pregnancy, lactation or lay"
Do not use in lactating cows. Do not use the product alone in cows with sub-clinical mastitis at drying off. Do not use in cows with clinical mastitis at drying off.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Special warnings
None
Special precautions for use
Special precautions for use in animals
It is good practice to observe dry cows regularly for signs of clinical mastitis. If a sealed quarter develops clinical mastitis, the affected quarter should be stripped out manually before appropriate therapy is instituted.
To reduce the risk of contamination, do not immerse the syringe in water.
Use the syringe only once.
Since the product does not have antimicrobial activity, in order to minimise the risk of acute mastitis due to poor infusion technique and lack of hygiene (see section "Adverse reactions (frequency and seriousness)"), it is crucial to follow the aseptic technique of administration described in section "Amounts to be administered and administration route".
Do not administer any other intramammary product following administration of the product.
In cows that may have sub-clinical mastitis, the product may be used following administration of a suitable dry cow antibiotic treatment to the infected quarter.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Avoid contact with skin or eyes.
Should skin or eye contact occur, wash the affected area thoroughly with water.
If irritation persists, seek medical advice and show this label to the doctor.
If you know that you are allergic to bismuth salts, avoid using this product.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Acute mastitis has been reported very rarely after use of this product, primarily due to the poor infusion technique and lack of hygiene. Please refer to sections "Special precautions for use" and "Amounts to be administered and administration route" regarding the importance of aseptic technique.
The frequency for adverse reactions is defined using the following convention:
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy:
As the product is not systemically absorbed following intramammary infusion, the product can be used in pregnant animals. At calving, the seal may be ingested by the calf. Ingestion of the product by the calf is safe and produces no adverse effects.
Lactation:
If accidentally used in a lactating cow, a transient rise in somatic cell count (up to 2-fold) may be observed. In such an event, strip out the seal manually, no additional precautions are necessary.
Interaction with other medicinal products and other forms of interaction
In clinical trials, the compatibility of the product has only been shown with a cloxacillin-containing dry cow preparation.
Amounts to be administered and administration route
Intramammary use.
Infuse the content of one syringe of the product into each udder quarter immediately after the last milking of the lactation (at drying off). Do not massage the teat or udder after infusion of the product.
Care must be taken not to introduce pathogens into the teat in order to reduce the risk of post-infusion mastitis (aseptic technique).
It is essential that the teat is thoroughly cleaned and disinfected, with surgical spirit or alcohol-impregnated wipes. The teats should be wiped until the wipes are no longer visibly dirty. Teats should be allowed to dry prior to infusion. Infuse aseptically and avoid contamination of the syringe nozzle. Following infusion it is advisable to use an appropriate teat dip or spray.
Under cold conditions the product may be warmed to room temperature in a warm environment to aid syringeability.
Overdose (symptoms, emergency procedures, antidotes), if necessary
Twice the recommended dose has been administered to cows without any clinical adverse effects.
Withdrawal periods
Meat & offal: Zero days
Milk: Zero hours
Pharmacological particulars
Pharmacotherapeutic group: Various products for teats and udder
ATCvet code: QG52X
Pharmacodynamic properties
Infusion of the product into each udder quarter produces a physical barrier against the penetration of bacteria thereby reducing the incidence of ascending intramammary infections during the dry period.
Pharmacokinetic particulars
Bismuth subnitrate, heavy is not systemically absorbed from the mammary gland, but resides as a seal in the teat until physically removed (Shown in cows with a dry period up to 100 days).
Pharmaceutical particulars
List of excipients
Aluminium di-/tri stearate
Povidone, iodinated
Liquid Paraffin
Major Incompatibilities
None known
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years
Special precautions for storage
No special precautions for storage.
Nature and composition of immediate packaging
Low density polyethylene syringe with a smooth tapered hermetically sealed nozzle.
Pack sizes:
Cartons of 24 and 60 syringes or buckets of 120 syringes including 24, 60 or 120 individually wrapped teat cleaning towels.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
Norbrook Laboratories Limited, Station Works, Newry, Co. Down, BT35 6JP Northern Ireland
Marketing Authorisation Number
Vm 02000/4361
Significant changes
Date of the first authorisation or date of renewal
05 August 2013
Date of revision of the text
November 2024
Any other information
Nil.
Legal category
Legal category: POM-V
GTIN
GTIN description:Noroseal 2.6g IMM: 120x Bucket
GTIN:5023534019282
GTIN description:Noroseal 2.6g IMM: 24x Pack
GTIN:5023534019268